中国医学创新2025，Vol.22Issue(4)：10-14,5.DOI:10.3969/j.issn.1674-4985.2025.04.003
阿托伐他汀协同阿贝西利联合氟维司群治疗HR+/HER2-型晚期乳腺癌患者的临床效果
Clinical Efficacy of Atorvastatin in Combination with Abemaciclib and Fulvestrant in the Treatment of HR+/HER2-Type Advanced Breast Cancer
摘要
Abstract
Objective:To investigate the clinical significance of Atorvastatin combined with Abemaciclib and Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor-2-negative(HR+/HER2-)type advanced breast cancer.Method:A total of 75 patients with HR+/HER2-type advanced breast cancer admitted to Jiujiang NO.1 People's Hospital from January 2022 to August 2023 were selected as research objects and randomly divided into control group,test group A and test group B,with 25 cases in each group.The control group was treated with placebo plus Abemaciclib combined with Fulvestrant,and test group A and test group B were treated with Atorvastatin plus Abemaciclib combined with Fulvestrant,including Atorvastatin 10 mg/time in test group A and Atorvastatin 20 mg/time in test group B,for a total of 6 treatment cycles.The clinical efficacy,the levels of tumor marker carcinoembryonic antigen(CEA)and breast cancer-associated antigen 153(CA153),blood lipid indexes before treatment and after 2,4 and 6 cycles of treatment and the occurrence of adverse reactions among three groups were compared.Result:The clinical effect of the three groups was compared,the difference was statistically significant(P<0.05).The clinical effective rate of test group A and test group B were higher than that of control group(P<0.05).The differences of CEA and CA153 levels in time and inter-group effects were statistically significant(P<0.05),and there was an interaction between time and groups(P<0.05).After 2,4 and 6 cycles of treatment,CEA and CA153 in test group A and test group B were lower than those in control group,and those in test group B were lower than those in test group A,with statistical significance(P<0.05).The levels of total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDL-C)and high density lipoprotein cholesterol(HDL-C)were statistically significant in time and inter-group effects(P<0.05),and HDL-C level had interaction between time and group(P<0.05).The HDL-C level of test group A and test group B was higher than that of control group,and the HDL-C level of test group B was higher than that of test group A,with statistical significance(P<0.05).The incidence of nausea and vomiting in test group B(8.00%)was lower than that in control group(40.00%),the difference was statistically significant(P<0.05).Conclusion:Atorvastatin can synergistically enhance the efficacy of Abemaciclib combined with Fulvestrant in the treatment of HR+/HER2-type advanced breast cancer,reduce the level of tumor markers,and decrease the occurrence of adverse reactions.关键词
晚期乳腺癌/阿托伐他汀/阿贝西利/氟维司群/肿瘤标志物/血脂水平Key words
Advanced breast cancer/Atorvastatin/Abemaciclib/Fulvestrant/Tumor markers/Lipid level引用本文复制引用
马丁丁,石鑫,左宏波,蒋轶,王志..阿托伐他汀协同阿贝西利联合氟维司群治疗HR+/HER2-型晚期乳腺癌患者的临床效果[J].中国医学创新,2025,22(4):10-14,5.基金项目
江西省卫生健康委科技计划项目(202311458) （202311458）
